Form 8-K - Current report:
SEC Accession No. 0001645666-25-000026
Filing Date
2025-05-13
Accepted
2025-05-13 16:05:48
Documents
14
Period of Report
2025-05-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kzr-20250513.htm   iXBRL 8-K 26326
2 EX-99.1 kezar1q25earningspr.htm EX-99.1 41743
  Complete submission text file 0001645666-25-000026.txt   202561

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kzr-20250513.xsd EX-101.SCH 1809
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kzr-20250513_lab.xml EX-101.LAB 22804
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kzr-20250513_pre.xml EX-101.PRE 13065
16 EXTRACTED XBRL INSTANCE DOCUMENT kzr-20250513_htm.xml XML 2822
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

EIN.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38542 | Film No.: 25939986
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)